We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study
Read MoreHide Full Article
Epizyme, Inc. (announced that the FDA has lifted the partial clinical hold on its lead cancer candidate tazemetostat’s study. In April, the FDA had paused U.S.-based enrollment of new patients in a phase I pediatric study of tazemetostat, after one patient who had advanced poorly differentiated chordoma developed secondary T-cell lymphoma (T-LBL). This patient then discontinued tazemetostat and started the treatment for T-cell lymphoma.
Epizyme is in the process of reopening enrollment in all of its company-sponsored studies in the United States, including the follicular lymphoma (FL) EZH2 activating mutation cohort of its phase II non-Hodgkin lymphoma study.
Shares of the company have lost 18.3% year to date compared with the industry’s decline of 2.7%.
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied as a monotherapy in ongoing phase II programs in certain molecularly defined solid tumors, including epithelioid sarcoma and other INI1-negative tumors, both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) forms of non-Hodgkin lymphoma (NHL), mesothelioma, and combination studies in DLBCL and NSCLC.
The company along with its team did a comprehensive assessment of the risk of secondary malignancies, including T-cell lymphoblastic lymphoma (T-LBL) potentially associated with tazemetostat. The company provided a thorough assessment of efficacy and safety data across all of its studies in hematological malignancies and solid tumors, in both adults and children. It convened a panel of external scientific and medical experts, who reviewed and validated the findings.
The company through constructive dialogues with the FDA resolved the clinical hold. Epizyme is now focused on its priorities, which include preparing for its first new drug application (NDA) submission for tazemetostat in epithelioid sarcoma and defining its registration path in FL. Epizyme will now engage with regulators in France and Germany to resolve the partial clinical holds, and resume enrollment in those countries.
Anika’s earnings per share estimates have increased from 57 cents to 95 cents for 2018 and from $1.02 to $1.49 for 2019 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 20.84%.
Ligand’s earnings per share estimates have moved up from $5.64 to $6.33 for 2018 and from $5.59 to $5.74 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 96% year to date.
Regeneron’s earnings per share estimates have increased from $18.99 to $20.38 for 2018 and from $21.15 to $21.74 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 8.18%. The stock has rallied 3.8% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study
Epizyme, Inc. ( announced that the FDA has lifted the partial clinical hold on its lead cancer candidate tazemetostat’s study. In April, the FDA had paused U.S.-based enrollment of new patients in a phase I pediatric study of tazemetostat, after one patient who had advanced poorly differentiated chordoma developed secondary T-cell lymphoma (T-LBL). This patient then discontinued tazemetostat and started the treatment for T-cell lymphoma.
Epizyme is in the process of reopening enrollment in all of its company-sponsored studies in the United States, including the follicular lymphoma (FL) EZH2 activating mutation cohort of its phase II non-Hodgkin lymphoma study.
Shares of the company have lost 18.3% year to date compared with the industry’s decline of 2.7%.
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied as a monotherapy in ongoing phase II programs in certain molecularly defined solid tumors, including epithelioid sarcoma and other INI1-negative tumors, both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) forms of non-Hodgkin lymphoma (NHL), mesothelioma, and combination studies in DLBCL and NSCLC.
The company along with its team did a comprehensive assessment of the risk of secondary malignancies, including T-cell lymphoblastic lymphoma (T-LBL) potentially associated with tazemetostat. The company provided a thorough assessment of efficacy and safety data across all of its studies in hematological malignancies and solid tumors, in both adults and children. It convened a panel of external scientific and medical experts, who reviewed and validated the findings.
The company through constructive dialogues with the FDA resolved the clinical hold. Epizyme is now focused on its priorities, which include preparing for its first new drug application (NDA) submission for tazemetostat in epithelioid sarcoma and defining its registration path in FL. Epizyme will now engage with regulators in France and Germany to resolve the partial clinical holds, and resume enrollment in those countries.
Epizyme, Inc. Price
Epizyme, Inc. Price | Epizyme, Inc. Quote
Zacks Rank & Stocks to Consider
Epizyme is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Anika Therapeutics Inc. (ANIK - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Regeneron Pharmaceuticals Inc. (REGN - Free Report) . While Anika and Ligand sport a Zacks Rank #1 (Strong Buy), Regeneron carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings per share estimates have increased from 57 cents to 95 cents for 2018 and from $1.02 to $1.49 for 2019 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 20.84%.
Ligand’s earnings per share estimates have moved up from $5.64 to $6.33 for 2018 and from $5.59 to $5.74 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 96% year to date.
Regeneron’s earnings per share estimates have increased from $18.99 to $20.38 for 2018 and from $21.15 to $21.74 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 8.18%. The stock has rallied 3.8% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>